Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

AI Briefing

• – Scholar Rock resubmits BLA for apitegromab to treat SMA in children and adults.
• – Apitegromab aims to improve lives of those with SMA by targeting myostatin biology.
• – Company to submit additional data to support BLA application.